[1] Luis Jimenez. Analysis of FDA Enforcement Reports (2012-2019) to Determine the Microbial Diversity Contaminated Non-Sterile and Sterile Drugs. American Pharmaceutical Review. 2019, 22, p. 48-73.
[2] David Westman. “Cost and impact of a bioburden incident”. Cytiva. April 12, 2017. https://www.cytivalifesciences.com/en/us/news-center/cost-andimpact-of-a-bioburden-incident-10001,(参照 2022-01-10).
[3] Barbara Unger. “FDA FY2019 drug inspection observations and trends”. Bioprocess online. December 6, 2019. https://www.bioprocessonline.com/doc/fda-fy-drug-inspectionobservations-and-trends-0001,(参照 2022-01-10)
[4] Barbara Unger. “An analysis of MHRA's latest annual GMP inspection deficiencies report”. Pharmaceutical online. January 11, 2021. https://www.pharmaceuticalonline.com/doc/an-analysis-of-mhra-s-latestannual-gmp-inspection-deficiencies-report-0001,(参照 2022-01-10)
[5] Michael J. Miller. Quality risk management and the economics of implementing rapid microbiological methods. European Pharmaceutical Review. 2009, 2, p. 66-73.
[6] Tsuguo Sasaki et al. Evaluation of a new method for identification of bacteria based on sequence homology of 16S rRNA gene. PDA J Pharm Sci Technol. 1997, 51, p. 242‒247.
[7] Shoji Narutaki et al. Identification of fungi based on the nucleotide sequence homology of their internal transcribed spacer1 region. PDA J Pharm Sci Technol. 2002, 56, p. 90-98.
[8] 厚⽣労働省. 第 18 改正⽇本薬局⽅ 参考情報 遺伝⼦解析による微⽣物の迅速 同定法〈G4-7-160〉.
[9] PIC/S. Guide to Good Manufacturing Practice for medicinal products. ANNEXES (PE 009-15). May1, 2021.
[10]厚⽣労働省. 第 18 改正⽇本薬局⽅ 参考情報 微⽣物迅速試験法〈G4-6- 170〉.
[11] Sao Paulo: “Ultra-rapid microbiology using ChemScan®RDI & regulatory requirements for validation of the RMM”. ABRASP Meeting. Oct 20, 2011.
[12] Jimenez Luis. Rapid methods for the microbiological surveillance. PDA J Pharm Sci Technol. 2001, 55, p. 278-285.
[13] José-Miguel Montenegro-Alvarado et al. “Pfizer case study: rapid microbial methods for manufacturing recovery after hurricane maría”. Pharmaceutical online. July 25, 2018. https://www.pharmaceuticalonline.com/doc/pfizercase-study-rapid-microbial-methods-for-manufacturing-recovery-afterhurricane-mar-a-0001,(参照 2022-01-10)
[14]Kawai Mako et al. Rapid enumeration of physiologically active bacteria in purified water used in the pharmaceutical manufacturing process. J Appl Microbiology 1999, 86, p. 496-504.
[15]Ramond Benoît et al. Enumeration of total viable microorganisms in an antibiotic raw material using ChemScan® solid phase cytometer. PDA J Pharm Sci Technol. 2000, 54, p. 320-331.
[16] Jennifer C Gray et al. Identification of micro-organisms after Milliflex rapid detection-a possibility to identify nonsterile findings in the Milliflex rapid sterility test. PDA J Pharm Sci Technol. 2011, 65, p. 42-54.
[17] Jones David et al. Method verification requirements for an advanced imaging system for microbial plate count enumeration. PDA J Pharm Sci Technol. 2018, 72, p. 199-212.
[18] The United States Pharmacopeia. General Information Chapter Validation of alternative microbiological methods.
[19]PDA. PDA Technical Report No. 33 (Revised 2013). Evaluation, validation and implementation of alternative and rapid microbiological methods.
[20] Hiroyuki Ogawa et al. Rapid and retrievable recording of big data of timelapse 3D shadow images of microbial colonies. Scientific Reports. 2015, May 15, 5:10061. doi: 10.1038/srep10061.
[21] Hiroyuki Ogawa et al. Noise-free accurate count of microbial colonies by time-lapse shadow image analysis. J Microbiological Methods. 2012, 91, p. 420-428. doi: 10.1016/j.mimet.2012.09.028.
[22] The United States Pharmacopeia. General Information Chapter . Microbiological evaluation of clean rooms and other controlled environments.
[23] FDA. Guidance for Industry: Sterile drug products produced by aseptic processing-current good manufacturing practice. October 2004.
[24]ISO 14698 Standards. Cleanrooms and associated controlled environmentsBiocontamination control.
[25] WHO. Environmental monitoring of clean rooms in vaccine manufacturing facilities. November 2012.
[26]Rajesh K. Gupta. Role of environmental monitoring and microbiological testing during manufacture of sterile drugs and biologics. American Pharmaceutical Review. 2014, 17, p. 46-55.
[27] David Bain et al. Microbial monitoring for biological drug substance manufacturing: an industry perspective. PDA J Pharm Sci and Tech. 2015, 69, p. 451-460.
[28] Anita Bawa et al. Mold control and detection in biological drug substance manufacturing facilities: an industry perspective. PDA J Pharm Sci and Tech. 2017, 71, p. 413-420.
[29] Aditya Prasad et al. Practical applications of bio-fluorescent particle counting in environmental monitoring investigations. PDA J Pharm Sci and Tech. 2020, 74, p. 318-323.
[30] Daniel B. Kearns et al. Swarming motility in undomesticated Bacillus subtilis. Molecular Microbiology. 2003, 49, p. 581-590.
[31] Avraham Be'er et al. Periodic reversals in Paenibacillus dendritiformis swarming. J Bacteriology. 2013, 195, p. 2709-2717.
[32] Thilo Kohler. Swarming of Pseudomonas aeruginosa is dependent on cellto-cell signaling and requires flagella and pili. J Bacteriology. 2000, p. 5990-5996.
[33] Adriana Bugno et al. Performance survey and comparison between rapid sterility testing method and pharmacopoeia sterility test. J Pharmaceutical Innovation. 2018, 13, p. 27‒35.
[34] Edward C. Tidswell et al. Microbiological test data-assuring data integrity. PDA J Pharm Sci and Tech. 2017, 72, p. 2-14. doi:10.5731/pdajpst.2017.008151
[35]Cheryl Platco et al. “Data integrity issues in microbial testing”. American Pharmaceutical Review. Oct 15, 2017. https://www.americanpharmaceuticalreview.com/FeaturedArticles/343521-Data-Integrity-Issues-in-Microbial-Testing/,(参照 2022- 01-10)
[36] Eric S. Langer. Average Batch Failure Rate Worsens. Genetic Engineering & Biotechnology News. October 1, 2016, 36, No. 17. https://www.genengnews.com/magazine/279/average-batch-failure-rateworsens/(参照 2022-01-10)
[37]Prefilled Syringes Market- Global Forecast to 2025. Markets and Markets
[38]統合イノベーション戦略推進会議決定. バイオ戦略 2020. 令和 2 年 6⽉26⽇.
[39]閣議決定. ワクチン開発・⽣産体制強化戦略. 令和 3 年 6 ⽉ 1 ⽇.
[40] FDA. Draft Guidance for Industry. Microbiological Quality Considerations in Non-Sterile Drug Manufacturing. September 2021.
[41]Results. Outsourced Pharmaceutical Manufacturing 2020: Current Trends & Future Prospects. November 2019.
[42]Rapid Microbiology Testing Market- Global Forecast to 2026. Markets and Markets, 230p
[43]坂本吉⼀監修. 第 17 改正 図説 ⽇本薬局⽅微⽣物試験法の⼿引き. ⽂教出 版, 2016, 260p.